Black Diamond Therapeutics Inc. - BDTX Quarterly EPS earnings growth

Corporate company logo of Black Diamond Therapeutics (BDTX)

Quarterly EPS variation demonstrates yield dynamics, where the metric level stands at -16.60. Black Diamond (BDTX) audience growth is tied to FDA decisions, as the commercial segment has not yet been established. Business stability is ensured by a lack of seasonality and macroeconomic resilience. Development relies on scientific alliances with oncology centers to combat rare genetic mutations.

blackdiamondtherapeutics.com (BDTX) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Black Diamond

- share price and consensus valuation forecast:
Fundamental company valuation:blackdiamondtherapeutics.com - BDTX
Flagship merchandise of blackdiamondtherapeutics.com

Black Diamond (BDTX) is developing high-tech targeted cancer therapy methods under venture risk conditions. This indicator captures the percentage change in earnings per share (EPS) per quarter, separating fundamental growth from market noise. Investors utilize this tool to verify the actual efficiency of the business. The quarterly EPS growth trend allows for an assessment of the company's resilience to speculative volatility. Analyzing this chart helps determine the entry point, minimizing the risk of purchasing the asset at the peak of unjustified optimism.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ELVN (Enliven Therapeutics, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share growth for the trailing year Relay Pharma|Nurix Therapeutics Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Biosciences|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|CGEM (cullinanoncology.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immuneering Inc. IMRX|Quarterly EPS earnings growth CCCC|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)